{"id":21321,"date":"2023-12-11T11:22:09","date_gmt":"2023-12-11T10:22:09","guid":{"rendered":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg"},"modified":"2023-12-11T11:25:42","modified_gmt":"2023-12-11T10:25:42","slug":"emn26_lenalidomide-vs-iberdomide","status":"inherit","type":"attachment","link":"https:\/\/www.anicecommunication.com\/it\/mieloma-multiplo-lo-studio-emn26-regista-miglioramenti-in-oltre-il-50-dei-pazienti\/emn26_lenalidomide-vs-iberdomide\/","title":{"rendered":"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide"},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"class_list":["post-21321","attachment","type-attachment","status-inherit","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide - IT Anice Communication<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide - IT Anice Communication\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg\" \/>\n<meta property=\"og:site_name\" content=\"IT Anice Communication\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/anicecommunication\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-11T10:25:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1002\" \/>\n\t<meta property=\"og:image:height\" content=\"515\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg\",\"url\":\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg\",\"name\":\"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide - IT Anice Communication\",\"isPartOf\":{\"@id\":\"https:\/\/www.anicecommunication.com\/it\/#website\"},\"datePublished\":\"2023-12-11T10:22:09+00:00\",\"dateModified\":\"2023-12-11T10:25:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anicecommunication.com\/it\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mieloma Multiplo: lo studio EMN26 regista miglioramenti in oltre il 50% dei pazienti\",\"item\":\"https:\/\/www.anicecommunication.com\/it\/mieloma-multiplo-lo-studio-emn26-regista-miglioramenti-in-oltre-il-50-dei-pazienti\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anicecommunication.com\/it\/#website\",\"url\":\"https:\/\/www.anicecommunication.com\/it\/\",\"name\":\"IT Anice Communication\",\"description\":\"Anicecommunication agenzia di pubbliche relazioni,  ufficio stampa, media relations, automotive e mobility a livello internazionale - Torino\",\"publisher\":{\"@id\":\"https:\/\/www.anicecommunication.com\/it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anicecommunication.com\/it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anicecommunication.com\/it\/#organization\",\"name\":\"Anice SRL - Agenzia di comunicazione, mobility and automotive media relations & PR in Italia, Europa\",\"alternateName\":\"Anicecommunication\",\"url\":\"https:\/\/www.anicecommunication.com\/it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.anicecommunication.com\/it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/06\/Anice_696x696.jpg\",\"contentUrl\":\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/06\/Anice_696x696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Anice SRL - Agenzia di comunicazione, mobility and automotive media relations & PR in Italia, Europa\"},\"image\":{\"@id\":\"https:\/\/www.anicecommunication.com\/it\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/anicecommunication\",\"https:\/\/x.com\/Anicecom\",\"https:\/\/instagram.com\/anicecom\/\",\"https:\/\/www.linkedin.com\/company\/anice-s-r-l-\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide - IT Anice Communication","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg","og_locale":"it_IT","og_type":"article","og_title":"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide - IT Anice Communication","og_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg","og_site_name":"IT Anice Communication","article_publisher":"https:\/\/www.facebook.com\/anicecommunication","article_modified_time":"2023-12-11T10:25:42+00:00","og_image":[{"width":1002,"height":515,"url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg","type":"image\/jpeg"}],"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg","url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg","name":"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide - IT Anice Communication","isPartOf":{"@id":"https:\/\/www.anicecommunication.com\/it\/#website"},"datePublished":"2023-12-11T10:22:09+00:00","dateModified":"2023-12-11T10:25:42+00:00","breadcrumb":{"@id":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anicecommunication.com\/it\/"},{"@type":"ListItem","position":2,"name":"Mieloma Multiplo: lo studio EMN26 regista miglioramenti in oltre il 50% dei pazienti","item":"https:\/\/www.anicecommunication.com\/it\/mieloma-multiplo-lo-studio-emn26-regista-miglioramenti-in-oltre-il-50-dei-pazienti\/"},{"@type":"ListItem","position":3,"name":"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide"}]},{"@type":"WebSite","@id":"https:\/\/www.anicecommunication.com\/it\/#website","url":"https:\/\/www.anicecommunication.com\/it\/","name":"IT Anice Communication","description":"Anicecommunication agenzia di pubbliche relazioni,  ufficio stampa, media relations, automotive e mobility a livello internazionale - Torino","publisher":{"@id":"https:\/\/www.anicecommunication.com\/it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anicecommunication.com\/it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.anicecommunication.com\/it\/#organization","name":"Anice SRL - Agenzia di comunicazione, mobility and automotive media relations & PR in Italia, Europa","alternateName":"Anicecommunication","url":"https:\/\/www.anicecommunication.com\/it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.anicecommunication.com\/it\/#\/schema\/logo\/image\/","url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/06\/Anice_696x696.jpg","contentUrl":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/06\/Anice_696x696.jpg","width":696,"height":696,"caption":"Anice SRL - Agenzia di comunicazione, mobility and automotive media relations & PR in Italia, Europa"},"image":{"@id":"https:\/\/www.anicecommunication.com\/it\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/anicecommunication","https:\/\/x.com\/Anicecom","https:\/\/instagram.com\/anicecom\/","https:\/\/www.linkedin.com\/company\/anice-s-r-l-"]}]}},"smush":{"stats":{"time":0.37,"bytes":250034,"percent":28.21,"size_before":886226,"size_after":636192,"lossy":0,"keep_exif":0,"api_version":"1.0"},"sizes":{"thumbnail":{"time":0.01,"bytes":14677,"percent":60.55,"size_before":24240,"size_after":9563},"medium":{"time":0.01,"bytes":15100,"percent":43.85,"size_before":34432,"size_after":19332},"fusion-200":{"time":0.01,"bytes":14781,"percent":59.47,"size_before":24854,"size_after":10073},"portfolio-five":{"time":0.01,"bytes":14745,"percent":56.64,"size_before":26031,"size_after":11286},"recent-works-thumbnail":{"time":0.03,"bytes":14417,"percent":81.85,"size_before":17613,"size_after":3196},"blog-medium":{"time":0.05,"bytes":15218,"percent":38.5,"size_before":39528,"size_after":24310},"portfolio-three":{"time":0.01,"bytes":15287,"percent":39.6,"size_before":38601,"size_after":23314},"fusion-400":{"time":0.01,"bytes":15518,"percent":34.96,"size_before":44383,"size_after":28865},"portfolio-one":{"time":0.01,"bytes":15928,"percent":26.42,"size_before":60298,"size_after":44370},"fusion-600":{"time":0.01,"bytes":16101,"percent":23.52,"size_before":68469,"size_after":52368},"portfolio-two":{"time":0.02,"bytes":15710,"percent":27.51,"size_before":57116,"size_after":41406},"blog-large":{"time":0.06,"bytes":15942,"percent":23.44,"size_before":68018,"size_after":52076},"recent-posts":{"time":0.02,"bytes":16476,"percent":18.11,"size_before":90956,"size_after":74480},"fusion-800":{"time":0.02,"bytes":16808,"percent":17.5,"size_before":96056,"size_after":79248},"medium_large":{"time":0.06,"bytes":16654,"percent":18.3,"size_before":91020,"size_after":74366},"portfolio-full":{"time":0.03,"bytes":16672,"percent":15.94,"size_before":104611,"size_after":87939}}},"description":{"rendered":"<p class=\"attachment\"><a data-rel=\"iLightbox[postimages]\" data-title=\"\" data-caption=\"\" href='https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg'><img decoding=\"async\" width=\"300\" height=\"154\" src=\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-300x154.jpg\" class=\"attachment-medium size-medium\" alt=\"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide\" srcset=\"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-200x103.jpg 200w, https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-300x154.jpg 300w, https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-400x206.jpg 400w, https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-600x308.jpg 600w, https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-768x395.jpg 768w, https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-800x411.jpg 800w, https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg 1002w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n"},"caption":{"rendered":""},"alt_text":"Mieloma Multiplo EMN26_Lenalidomide-vs-Iberdomide","media_type":"image","mime_type":"image\/jpeg","media_details":{"width":1002,"height":515,"file":"2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg","filesize":469408,"sizes":{"medium":{"file":"EMN26_Lenalidomide-vs-Iberdomide-300x154.jpg","width":300,"height":154,"filesize":34432,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-300x154.jpg"},"thumbnail":{"file":"EMN26_Lenalidomide-vs-Iberdomide-150x150.jpg","width":150,"height":150,"filesize":24240,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-150x150.jpg"},"medium_large":{"file":"EMN26_Lenalidomide-vs-Iberdomide-768x395.jpg","width":768,"height":395,"filesize":91020,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-768x395.jpg"},"blog-large":{"file":"EMN26_Lenalidomide-vs-Iberdomide-669x272.jpg","width":669,"height":272,"filesize":68018,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-669x272.jpg"},"blog-medium":{"file":"EMN26_Lenalidomide-vs-Iberdomide-320x202.jpg","width":320,"height":202,"filesize":39528,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-320x202.jpg"},"recent-posts":{"file":"EMN26_Lenalidomide-vs-Iberdomide-700x441.jpg","width":700,"height":441,"filesize":90956,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-700x441.jpg"},"recent-works-thumbnail":{"file":"EMN26_Lenalidomide-vs-Iberdomide-66x66.jpg","width":66,"height":66,"filesize":17613,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-66x66.jpg"},"fusion-200":{"file":"EMN26_Lenalidomide-vs-Iberdomide-200x103.jpg","width":200,"height":103,"filesize":24854,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-200x103.jpg"},"fusion-400":{"file":"EMN26_Lenalidomide-vs-Iberdomide-400x206.jpg","width":400,"height":206,"filesize":44383,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-400x206.jpg"},"fusion-600":{"file":"EMN26_Lenalidomide-vs-Iberdomide-600x308.jpg","width":600,"height":308,"filesize":68469,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-600x308.jpg"},"fusion-800":{"file":"EMN26_Lenalidomide-vs-Iberdomide-800x411.jpg","width":800,"height":411,"filesize":96056,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-800x411.jpg"},"portfolio-full":{"file":"EMN26_Lenalidomide-vs-Iberdomide-940x400.jpg","width":940,"height":400,"filesize":104611,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-940x400.jpg"},"portfolio-one":{"file":"EMN26_Lenalidomide-vs-Iberdomide-540x272.jpg","width":540,"height":272,"filesize":60298,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-540x272.jpg"},"portfolio-two":{"file":"EMN26_Lenalidomide-vs-Iberdomide-460x295.jpg","width":460,"height":295,"filesize":57116,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-460x295.jpg"},"portfolio-three":{"file":"EMN26_Lenalidomide-vs-Iberdomide-300x214.jpg","width":300,"height":214,"filesize":38601,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-300x214.jpg"},"portfolio-five":{"file":"EMN26_Lenalidomide-vs-Iberdomide-177x142.jpg","width":177,"height":142,"filesize":26031,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide-177x142.jpg"},"full":{"file":"EMN26_Lenalidomide-vs-Iberdomide.jpg","width":1002,"height":515,"mime_type":"image\/jpeg","source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg"}},"image_meta":{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1","keywords":[]}},"post":21320,"source_url":"https:\/\/www.anicecommunication.com\/it\/wp-content\/uploads\/sites\/3\/2023\/12\/EMN26_Lenalidomide-vs-Iberdomide.jpg","_links":{"self":[{"href":"https:\/\/www.anicecommunication.com\/it\/wp-json\/wp\/v2\/media\/21321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anicecommunication.com\/it\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.anicecommunication.com\/it\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.anicecommunication.com\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anicecommunication.com\/it\/wp-json\/wp\/v2\/comments?post=21321"}]}}